Astrazeneca (AZN) Gross Profit (2009 - 2026)

Astrazeneca's Gross Profit history runs 18 years deep, the most recent figure standing at $12.9 billion for Q2 2026.

• In Q2 2026, Gross Profit rose 7.32% year-over-year to $12.9 billion; the TTM figure through Jun 2026 stood at $50.2 billion (up 9.28% YoY), while the FY2025 annual figure was $48.1 billion, up 9.67% from the prior year.
• Gross Profit for Q2 2026 stood at $12.9 billion, up from $12.6 billion in the prior quarter.
• The five-year high for Gross Profit was $27.8 billion in Q4 2023, with the low at $7.8 billion in Q2 2022.
• The 5-year median for Gross Profit is $10.6 billion (2024), against an average of $11.4 billion.
• The sharpest annual moves came in 2023 and 2024: Gross Profit surged 234.98% in 2023, then sank 56.28% in 2024.
• Astrazeneca's Gross Profit stood at $8.3 billion in 2022, then soared by 234.98% to $27.8 billion in 2023, then tumbled by 56.28% to $12.2 billion in 2024, then increased by 1.8% to $12.4 billion in 2025, then grew by 3.84% to $12.9 billion in 2026.
• Business Quant data shows AZN's Gross Profit at $12.9 billion in Q2 2026, $12.6 billion in Q1 2026, and $12.4 billion in Q4 2025.